TCGA-60-2707-01A-01R-0851-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- ANGIOGENESIS+0.600
- TGF_BETA_SIGNALING+0.590
- TNFA_SIGNALING_VIA_NFKB+0.570
- HYPOXIA+0.530
- APOPTOSIS+0.480
- APICAL_JUNCTION+0.470
- INFLAMMATORY_RESPONSE+0.460
- COAGULATION+0.440
- APICAL_SURFACE+0.430
Top 10 suppressed
- MYC_TARGETS_V2-0.240
- OXIDATIVE_PHOSPHORYLATION-0.180
- E2F_TARGETS-0.130
- MYC_TARGETS_V1-0.120
- BILE_ACID_METABOLISM-0.090
- DNA_REPAIR-0.080
- SPERMATOGENESIS-0.080
- PANCREAS_BETA_CELLS-0.070
- ALLOGRAFT_REJECTION+0.040
- G2M_CHECKPOINT+0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-85-8481-01A-11R-2326-07 | — | cohortSQ1 | 0.927 |
| 2 | TCGA-43-6771-01A-11R-1820-07 | — | cohortSQ1 | 0.911 |
| 3 | s0122159 | — | — | 0.884 |
| 4 | SRR26320076 | — | — | 0.880 |
| 5 | TCGA-BA-5557-01A-01R-1514-07 | — | — | 0.879 |
| 6 | TCGA-50-5939-01A-11R-1628-07 | — | cohortA1 | 0.873 |
| 7 | BS_WRHDP7WF | Posterior Fossa Ependymoma | — | 0.864 |
| 8 | MBCProject_4733_T1_RNA | — | A | 0.862 |
| 9 | SRR10900576 | — | — | 0.862 |
| 10 | TCGA-CN-6020-01A-11R-1686-07 | — | — | 0.860 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.600 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.590 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| HYPOXIA | 0.530 | Idelalisib | — uncovered |
| APOPTOSIS | 0.480 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.470 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.460 | Idelalisib | — uncovered |
| COAGULATION | 0.440 | Binimetinib | — uncovered |
| APICAL_SURFACE | 0.430 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.420 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.410 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.390 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.340 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.320 | Inavolisib | — uncovered |